TIAP announces New President and CEO
February 12, 2020 06:30 ET | Toronto Innovation Acceleration Partners
Toronto, Ontario, Feb. 12, 2020 (GLOBE NEWSWIRE) -- The Board of Directors of TIAP – Toronto Innovation Acceleration Partners (formerly MaRS Innovation) – is pleased to announce the appointment of...
Toronto Innovation Acceleration Partners (TIAP) adds novel KRAS oncology project to its LAB150 portfolio
December 12, 2019 07:00 ET | Toronto Innovation Acceleration Partners
Toronto, ON, Dec. 12, 2019 (GLOBE NEWSWIRE) -- The low survival rates of three of the four most lethal cancers in North America - pancreatic, colorectal and lung - are associated with KRAS...
Tehama and Bitnobi Partner to Lay Foundation for a Data Trust Platform
October 17, 2019 07:00 ET | Bitnobi
Toronto and Ottawa, Ontario, Oct. 17, 2019 (GLOBE NEWSWIRE) -- Tehama, the leading SaaS solution to secure mission critical and data sensitive systems when granting access to global employees and...
MaRS Innovation Launches New Drug Discovery Program Targeting Rare and Disabling Developmental Disorder
July 15, 2019 07:00 ET | MaRS Innovation
Toronto, ON, July 15, 2019 (GLOBE NEWSWIRE) -- MaRS Innovation announced today that it is partnering with Dr. James Eubanks at the University Health Network (UHN) to develop a new treatment for Rett...
Mental Health is Focus of New High-Potential Anti-Depression Project from MaRS Innovation and the Centre for Addiction and Mental Health
June 11, 2019 07:00 ET | MaRS Innovation
Toronto, ON, June 11, 2019 (GLOBE NEWSWIRE) -- It is estimated that 5% of the global population is affected by Major Depressive Disorder (MDD) at any given time. While there are many...
MaRS Innovation adds to growing portfolio with two new LAB150 projects to create novel therapeutics for Cystic Fibrosis and Respiratory Syncytial Virus.
February 27, 2019 07:00 ET | MaRS Innovation
Toronto, ON, Feb. 27, 2019 (GLOBE NEWSWIRE) -- MaRS Innovation announced today the concurrent launch of two new LAB150 projects. These projects build on breakthroughs in disease-focused scientific...
MaRS Innovation’s Triphase Accelerator Announces New Partnership with Celgene for First-in-class WDR5 Leukemia Therapy
January 29, 2019 08:00 ET | MaRS Innovation
Toronto, ON, Jan. 29, 2019 (GLOBE NEWSWIRE) -- Triphase Accelerator, a Toronto-based drug development company, has entered into a new strategic partnership with Celgene Corporation. The focus of the...
Fibrocor, a MaRS Innovation portfolio company, announces deal with Galapagos
January 07, 2019 10:43 ET | MaRS Innovation
Toronto, ON, Jan. 07, 2019 (GLOBE NEWSWIRE) -- Fibrocor Therapeutics, a privately held Canadian company, and Galapagos NV, a Belgo-Dutch pharmaceutical research company, have announced the formation...
LAB150 awards its second drug discovery project from Canada’s largest research based Hospital, The University Health Network (UHN)
October 04, 2018 08:00 ET | MaRS Innovation
Toronto, ON, Oct. 04, 2018 (GLOBE NEWSWIRE) -- MaRS Innovation announced today the second project to be developed under their LAB150 partnership with Evotec.   The project aims to develop a...
Vasomune Therapeutics and AnGes, Inc. enter into a Multi-Million Dollar Global Co-Development Agreement to Advance an Innovative Platform Targeting Vascular Leakage
July 31, 2018 07:00 ET | AnGes, Inc.
Tokyo, Japan and Toronto, Ontario, July 31, 2018 (GLOBE NEWSWIRE) -- Vasomune Therapeutics (“Vasomune”), a Toronto-based spin-out from Sunnybrook Research Institute and MaRS Innovation, and AnGes,...